Amplify Treatments, Testing and Advancements ETF
GERM
GERM was delisted on the 5th of September, 2024.
25 hedge funds and large institutions have $5.23M invested in Amplify Treatments, Testing and Advancements ETF in 2020 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 9 increasing their positions, 2 reducing their positions, and 4 closing their positions.
350% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 2
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
25% more funds holding
Funds holding: 20 → 25 (+5)
23% more capital invested
Capital invested by funds: $4.24M → $5.23M (+$990K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
+$820K |
| 2 |
G
Gainplan
Bloomfield Hills,
Michigan
|
+$291K |
| 3 |
APA
American Portfolios Advisors
Holbrook,
New York
|
+$291K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$283K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
+$182K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$742K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$453K |
| 3 |
WS
Wedbush Securities
Los Angeles,
California
|
-$385K |
| 4 |
CA
Clearstead Advisors
Cleveland,
Ohio
|
-$24K |
| 5 |
JWM
Jeppson Wealth Management
Manhattan Beach,
California
|
-$6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Jane Street
New York
| – | -$742K | -26,843 | Closed |
|
|
WS
27
Wedbush Securities
Los Angeles,
California
| – | -$385K | -13,924 | Closed |
|
|
CA
28
Clearstead Advisors
Cleveland,
Ohio
| – | -$24K | -860 | Closed |
|
|
JWM
29
Jeppson Wealth Management
Manhattan Beach,
California
| – | -$6K | -200 | Closed |
|
GERM Hedge Fund Activity: Q4 2020 in Review
25 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Amplify Treatments, Testing and Advancements ETF (GERM) for Q4 2020, worth a combined $5.23M — up 23% from $4.24M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new GERM positions and 4 closed out — a net gain of 5 holders — while 9 added to existing stakes and 2 trimmed.
The largest buyer was LPL Financial, opening a new position worth an estimated $820K. The largest seller was Jane Street, exiting entirely with an estimated $742K sold.
- 25 institutional investors held Amplify Treatments, Testing and Advancements ETF (GERM) as of Q4 2020, up from 20 in Q3 2020.
- Funds reported $5.23M of Amplify Treatments, Testing and Advancements ETF stock for Q4 2020, up 23% quarter-over-quarter.
- 9 funds opened new Amplify Treatments, Testing and Advancements ETF positions in Q4 2020 and 4 closed out, a net change of +5 holders.
- The largest Amplify Treatments, Testing and Advancements ETF buyer in Q4 2020 was LPL Financial, an estimated $820K added.
- The largest Amplify Treatments, Testing and Advancements ETF seller in Q4 2020 was Jane Street, an estimated $742K sold.
Based on aggregated 13F filings for Q4 2020.